



ASSISTANCE  
PUBLIQUE  HÔPITAUX  
DE PARIS

 Université  
Paris Cité

 AP-HP. Centre  
Université  
de Paris



Samedi 13 mai 2023  
19<sup>ème</sup> JOURNÉE DE GASTRO-ENTEROLOGIE  
DE L'HOPITAL COCHIN  
(APHP.Centre Université Paris Cité)

# Tumeurs neuro endocrines digestives

**Romain Coriat**

Service de gastroentérologie, d'endoscopie et d'oncologie digestive

**CHU Cochin**

*romain.coriat@aphp.fr*

# 1 entité particulière

## • Les TNE de l'appendice

Registre épidémiologique Nord-Américain (SEER)

les TNE digestives les plus fréquentes sont celles développées aux dépens de l'intestin grêle ou du rectum

### Taux d'incidence normalise selon l'Age

Intestin grêle 1,2/100 000/an

Rectum 1,2/100 000/an

Pancréas 0,8/100 000/an


Estomac 0,4/100 000/an

**Appendice 0,4/100 000/an**




*En France: 300 cas par an*

Figure 3. Median Overall Survival (OS) of Neuroendocrine Tumors



# 1 entité particulière

## • Les TNE de l'appendice



Les TNE de l'appendice sont généralement découvertes fortuitement sur la pièce d'appendicectomie, généralement réséquée sans ganglion lymphatique examinable

*Les métastases à distance sont exceptionnelles.*

# Les TNE de l'appendice




## Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study

*Cohorte rétrospective  
40 hôpitaux (15 pays européens)  
TNE de l'appendice*

*Taille : 1 à 2 cm  
Résection R0*

*Période : Janvier 2000 – Décembre 2010*

*Patients : Appendicectomie +/- Colectomie droite complémentaire*



# Les TNE de l'appendice

*TNE de l'appendice*  
*Taille : 1 à 2 cm*  
*Résection R0*


|                                    | Appendectomy<br>(n=163) | Right-sided<br>hemicolecotomy<br>(n=115) | p value |
|------------------------------------|-------------------------|--|---------|
| <b>Demographic characteristics</b> |                         |  |         |
| Age at initial surgery, years      | 36.2 (18.4)             | 35.9 (17.9)                              | 0.90    |
| Sex                                |                         |  |         |
| Male                               | 71 (44%)                | 39 (34%)                                 | 0.11    |
| Female                             | 92 (56%)                | 76 (66%)                                 | ..      |
| <b>Histopathological features</b>  |                         |  |         |
| Tumour location                    |                         |  |         |
| Tip or middle                      | 144 (88%)               | 83 (72%)                                 | 0.0026  |
| Base                               | 11 (7%)                 | 17 (15%)                                 | ..      |
| Not available                      | 8 (5%)                  | 15 (13%)                                 | ..      |
| Tumour grade                       |                         |  |         |
| Grade 1                            | 142 (87%)               | 93 (81%)                                 | 0.36    |
| Grade 2                            | 12 (7%)                 | 13 (11%)                                 | ..      |
| Not available                      | 9 (6%)                  | 9 (8%)                                   | ..      |
| Resection margin                   |                         |  |         |
| R0                                 | 156 (96%)               | 96 (83%)                                 | 0.0001  |
| R1                                 | 1 (1%)                  | 15 (13%)                                 | ..      |
| Not available                      | 6 (4%)                  | 4 (3%)                                   | ..      |
| Lymphovascular invasion            |                         |  |         |
| Yes                                | 28 (17%)                | 33 (29%)                                 | 0.073   |
| No                                 | 119 (73%)               | 72 (63%)                                 | ..      |
| Not available                      | 16 (10%)                | 10 (9%)                                  | ..      |
| Mesoappendix infiltration          |                         |  |         |
| ≤3 mm                              | 42 (26%)                | 38 (33%)                                 | 0.10    |
| >3 mm                              | 13 (8%)                 | 15 (13%)                                 | ..      |
| Not available                      | 108 (66%)               | 62 (54%)                                 | ..      |
| Tumour size, cm                    |                         |  |         |
| 1.0-1.5                            | 135 (83%)               | 86 (75%)                                 | 0.10    |
| 1.6-2.0                            | 28 (17%)                | 29 (25%)                                 | ..      |

# Les TNE de l'appendice


*TNE de l'appendice*

*Taille : 1 à 2 cm*

*Résection R0*



|   | 0       | 5       | 10       | 15      | 20      |
|---|---------|---------|----------|---------|---------|
| <b>Number at risk (number censored)</b> |         |         |          |         |         |
| Appendectomy                            | 163 (0) | 147 (9) | 134 (16) | 50 (95) | 4 (141) |
| Right-sided hemicolectomy               | 115 (0) | 105 (3) | 96 (9)   | 38 (65) | 3 (101) |



|   | 0       | 5       | 10       | 15      | 20      |
|---|---------|---------|----------|---------|---------|
| <b>Number at risk (number censored)</b> |         |         |          |         |         |
| Appendectomy                            | 122 (0) | 115 (7) | 109 (12) | 41 (78) | 4 (116) |
| Right-sided hemicolectomy               | 93 (0)  | 91 (1)  | 85 (6)   | 35 (56) | 2 (89)  |

*L'intérêt de la colectomie se discute de plus en plus.*


# Les TNE de l'appendice chez l'enfant



Contents lists available at [ScienceDirect](#)

European Journal of Surgical Oncology

journal homepage: [www.ejso.com](http://www.ejso.com)



Review Article

## Management and outcome of high-risk neuroendocrine tumors of the appendix in children; A systematic review



Paul van Amstel <sup>a, b, c, \*</sup>, Amber Mahieu <sup>a</sup>, Roel Bakx <sup>a, b</sup>, Ralph de Vries <sup>d</sup>,  
Martine F. Raphael <sup>e</sup>, Joep P.M. Derikx <sup>a, b, c</sup>, L.W. Ernest van Heurn <sup>a, b, c</sup>,  
Ramon R. Gorter <sup>a, b, c</sup>

<sup>a</sup> Emma Children's Hospital, Amsterdam UMC location, University of Amsterdam, Pediatric Surgery, Meibergdreef 9, Amsterdam, the Netherlands

<sup>b</sup> Amsterdam Reproduction & Development, Amsterdam, the Netherlands

<sup>c</sup> Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, the Netherlands

<sup>d</sup> Vrije Universiteit Amsterdam, University Library, Amsterdam, the Netherlands

<sup>e</sup> Emma Children's Hospital, Amsterdam UMC location, University of Amsterdam, Pediatric Oncology, Meibergdreef 9, Amsterdam, the Netherlands

# Les TNE de l'appendice chez l'enfant

## TNE de l'appendice

P. van Amstel, A. Mahieu, R. Balci et al.

European Journal of Surgical Oncology 49 (2023) 329–338

**Table 1**  
General characteristics.

| Author               | Study design         | Age range (years) | No. of patients | pT1 | pT2 | pT3 | High-risk NETs | Indications for secondary surgery | Intervention group | Control group | Follow-up period (months) |
|----------------------|----------------------|-------------------|-----------------|-----|-----|-----|----------------|-----------------------------------|--------------------|---------------|---------------------------|
| Akova (2018)         | Retrospective cohort | 10–16             | 10              | 4   | 6   | 0   | 4              | G2: 3; G2 + MI: 1                 | 0                  | 4             | 2–89                      |
| Bamo (2018)          | Retrospective cohort | 13–18             | 8               | 3   | 5   | 0   | 4              | Base: 2; MI: 2                    | 2                  | 2             | 2–326                     |
| Bakberger (2013)     | Prospective cohort   | 4–20              | 237             | 165 | 52  | 10  | 21             | TS: 10                            | 9                  | 1             | 0–153                     |
| Corpron (1995)       | Retrospective cohort | 6–19              | 22              | 8   | 5   | 0   | 4              | MI: 4                             | 1                  | 3             | 18–360                    |
| Dall'igna (2005)     | Retrospective cohort | 5–17              | 14              | 6   | 4   | 0   | 3              | MI + R1: 3                        | 3                  | 0             | 24–214                    |
| De Lambert (2016)    | Retrospective cohort | 5–17              | 114             | ?   | ?   | 10  | 29             | MI: 16; TS: 10 LM: 2; G2: 1       | 10                 | 19            | 1–120                     |
| Fernandez (2015)     | Retrospective cohort | 8–17              | 28              | 17  | 10  | 1   | 5              | MI: 3; LVI: 1; TS: 1              | 5                  | 0             | 12–156                    |
| Hatzipantelis (2010) | Retrospective cohort | 4–13              | 19              | 18  | 1   | 0   | 1              | MI: 1                             | 0                  | 1             | 6–118                     |
| Henderson (2014)     | Retrospective cohort | 8–15              | 27              | 13  | 10  | 0   | 7              | MI: 7                             | 0                  | 7             | 1–193                     |
| Jonsson (1989)       | Retrospective cohort | 4–15              | 18              | 17  | 1   | 0   | 1              | MI: 1                             | 0                  | 1             | 26–351                    |
| Kartal (2022)        | Retrospective cohort | 6–17              | 15              | 4   | 10  | 1   | 2              | TS: 1, MI: 1                      | 0                  | 2             | 3–159                     |
| Kim (2014)           | Retrospective cohort | 7–17              | 13              | 10  | 2   | 1   | 1              | TS: 1                             | 1                  | 0             | 8–154                     |
| Kulkarni (2013)      | Retrospective cohort | 10–18             | 7               | 5   | 2   | 0   | 1              | LVI: 1                            | 1*                 | 0             | 1–84                      |
| Moertel (1990)       | Retrospective cohort | 6–20              | 23              | 15  | 3   | 3   | 6              | LVI: 3; TS: 3                     | 2                  | 4             | 9–612                     |
| Neves (2006)         | Retrospective cohort | 4–17              | 8               | 5   | 3   | 0   | 1              | MI: 1                             | 1                  | 0             | 42                        |
| Njere (2018)         | Retrospective cohort | 8–16              | 11              | 6   | 5   | 0   | 2              | missing                           | 1                  | 1             | 1–72                      |
| Parikh (2018)        | Retrospective cohort | 0–19              | 109             | ?   | ?   | 11  | 11             | TS: 11                            | 8                  | 3             | 120–312                   |
| Pelizzo (2001)       | Retrospective cohort | 8–18              | 10              | 8   | 0   | 2   | 2              | TS: 2                             | 2                  | 0             | 36                        |
| Pérez-Albert (2017)  | Retrospective cohort | 8–16              | 17              | 14  | 2   | 0   | 1              | MI + base + R1: 1                 | 0                  | 1             | 4–92                      |
| Prommegger (2002)    | Retrospective cohort | 6–16              | 36              | 4   | 4   | 0   | 4              | Base or MI: 4                     | 0                  | 4             | 2–360                     |
| Rana-weera (2019)    | Retrospective cohort | 0–18              | 32              | 20  | 7   | 5   | 12             | TS: 5; missing: 7                 | 12                 | 0             | 1–60                      |
| Ryden (1975)         | Retrospective cohort | 7–14              | 30              | 17  | 1   | 1   | 1              | TS: 1                             | 0                  | 1             | 24–288                    |
| Scott (2011)         | Retrospective cohort | 7–15              | 47              | 21  | 14  | 2   | 2              | TS: 2                             | 1                  | 1             | ?                         |
| Sommer (2019)        | Retrospective cohort | 5–16              | 40              | 31  | 5   | 1   | 2              | R1: 1; TS: 1                      | 1                  | 1             | 0–158                     |
| Spunt (2000)         | Retrospective cohort | 8–15              | 5               | 1   | 3   | 0   | 2              | R1 + MI: 2                        | 2                  | 0             | 6–244                     |
| Vandeveld (2015)     | Retrospective cohort | 9–15              | 21              | 15  | 5   | 0   | 4              | LVI: 2; MI + LVI: 1; ME: 1        | 0                  | 4             | 0–6                       |
| Virgone (2014)       | Prospective cohort   | 0.75–17           | 113             | ?   | ?   | 5   | 5              | TS: 5                             | 1                  | 4             | 1–151                     |
| Wu (2017)            | Retrospective cohort | 6–17              | 45              | 30  | 5   | 0   | 5              | MI: 2; missing: 3                 | 1                  | 4             | 1–150                     |
| Yalcin (2022)        | Retrospective cohort | 7–16              | 33              | 19  | 5   | 2   | 2              | TS: 2                             | 0                  | 2             | 5–227                     |

MI: Mesoappendiceal invasion; LVI: lymphovascular invasion; TS: Tumor size; R1: Positive resection margin.

\* Primary surgery was a total colectomy for familial adenomatous polyposis (FAP).

# Les TNE de l'appendice chez l'enfant

**Table 1**  
General characteristics.

| Author | Study design | Age range | No. of patients | pT1 | pT2 | pT3 | High-risk | Indications for secondary surgery | Intervention | Control | Follow-up period (months) |
|--------|--------------|-----------|-----------------|-----|-----|-----|-----------|-----------------------------------|--------------|---------|---------------------------|
|--------|--------------|-----------|-----------------|-----|-----|-----|-----------|-----------------------------------|--------------|---------|---------------------------|

## ABSTRACT

This study systematically reviewed the literature to investigate the value of secondary surgery for children with a high-risk neuroendocrine tumor (NET) of appendix. A systematic search was performed in PubMed, Embase and Web of Science. All randomized controlled trials, cohort studies, and case series reporting on the management and outcomes of patients (<20 years) with a histopathologically proven NET of the appendix were eligible for inclusion. Two authors independently selected eligible articles, assessed risk of bias, and extracted data. The outcomes of patients with a high-risk NET treated with secondary surgery were compared to those treated without secondary surgery. Primary outcomes were recurrence rate and disease-free survival. The literature search yielded 667 articles, of which 29 were included. These studies reported on 1112 patients, of whom 145 (13%) had high-risk NET. Heterogeneity between studies was large and risk of bias was serious in 26 and moderate in three studies. Secondary surgery after primary appendectomy was performed in 64 of 145 patients (44%). Length of follow-up ranged between 0 and 612 months. In both treatment groups no recurrences were reported, and thus disease-free survival was 100%. Based on current literature, the value of secondary surgery for pediatric high-risk NET of the appendix may be questioned. However, evidence is scarce, of low-quality, and heterogeneity between studies is large. Large international studies with adequate follow-up are needed to generate high-quality evidence on this topic.

© 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

|                   |                      |         |     |    |   |   |   |                            |   |   |       |
|-------------------|----------------------|---------|-----|----|---|---|---|----------------------------|---|---|-------|
| Vandevelde (2015) | Retrospective cohort | 9–15    | 21  | 15 | 5 | 0 | 4 | LVI: 2; MI + LVI: 1; ME: 1 | 0 | 4 | 0–6   |
| Virgone (2014)    | Prospective cohort   | 0.75–17 | 113 | 7  | 7 | 5 | 5 | TS: 5                      | 1 | 4 | 1–151 |
| Wu (2017)         | Retrospective cohort | 6–17    | 45  | 30 | 5 | 0 | 5 | MI: 2; missing: 3          | 1 | 4 | 1–150 |
| Yalcin (2022)     | Retrospective cohort | 7–16    | 33  | 19 | 5 | 2 | 2 | TS: 2                      | 0 | 2 | 5–227 |

MI: Mesoappendiceal invasion; LVI: lymphovascular invasion; TS: Tumor size; RI: Positive resection margin.

\* Primary surgery was a total colectomy for familial adenomatous polyposis (FAP).

# Les TNE de l'appendice chez l'enfant

TNE de l'appendice

P. van Amstel, A. Mahieu, R. Balx et al.

European Journal of Surgical Oncology 49 (2023) 329–338

**Table 1**  
General characteristics.

| Author | Study design | Age range | No. of patients | pT1 | pT2 | pT3 | High-risk | Indications for secondary surgery | Intervention | Control | Follow-up period |
|--------|--------------|-----------|-----------------|-----|-----|-----|-----------|-----------------------------------|--------------|---------|------------------|
|--------|--------------|-----------|-----------------|-----|-----|-----|-----------|-----------------------------------|--------------|---------|------------------|

## ABSTRACT

This study systematically reviewed the literature to investigate the value of secondary surgery for children with a high-risk neuroendocrine tumor (NET) of appendix. A systematic search was performed in PubMed, Embase and Web of Science. All randomized controlled trials, cohort studies, and case series reporting on the management and outcomes of patients (<20 years) with a histopathologically confirmed NET of the appendix were eligible for inclusion. Two authors independently assessed risk of bias, and extracted data. The outcomes of patients who underwent secondary surgery were compared to those who did not. The results showed that secondary surgery in children with high-risk NET of the appendix is associated with a significantly higher recurrence rate and lower overall survival compared to non-surgical management. **Nonetheless, in current literature no recurrences have been reported and disease-free survival seems to be 100% in the pediatric population. Therefore the clinical course of NETs of the appendix seems to be more benign in children compared to the adult population, although international studies with adequate follow-up are needed on this topic.**

© 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

|                   |                      |         |     |    |   |   |   |                            |   |   |       |
|-------------------|----------------------|---------|-----|----|---|---|---|----------------------------|---|---|-------|
| Vandevelde (2015) | Retrospective cohort | 9–15    | 21  | 15 | 5 | 0 | 4 | LVI: 2; MI + LVI: 1; ME: 1 | 0 | 4 | 0–6   |
| Virgone (2014)    | Prospective cohort   | 0.75–17 | 113 | 7  | 7 | 5 | 5 | TS: 5                      | 1 | 4 | 1–151 |
| Wu (2017)         | Retrospective cohort | 6–17    | 45  | 30 | 5 | 0 | 5 | MI: 2; missing: 3          | 1 | 4 | 1–150 |
| Yalcin (2022)     | Retrospective cohort | 7–16    | 33  | 19 | 5 | 2 | 2 | TS: 2                      | 0 | 2 | 5–227 |

MI: Mesoappendiceal invasion; LVI: lymphovascular invasion; TS: Tumor size; RI: Positive resection margin.  
\* Primary surgery was a total colectomy for familial adenomatous polyposis (FAP).

# Les TNE de l'appendice

## • En cas de doute

Thésaurus National de Cancérologie Digestive®

### Chapitre : 11 Néoplasies Neuroendocrines (NNE) digestives

Date de cette version :  
**17/03/2020**

Date de dernière mise à jour à vérifier sur [www.tnkd.org](http://www.tnkd.org) ou [www.snfge.org](http://www.snfge.org)

GRUPE DE TRAVAIL : G. Cadiot (Reims), coordonnateur,

## • Dans les TNE de l'appendice: Les points à connaître

- *Tumeur très peu agressive*
- *Souvent avec un diagnostic a posteriori chez un patient jeune (mineur)*
- *Besoin d'une analyse anapath avec les 6 critères*  
(Envahissement de la base? Franchissement de la séreuse? Emboles veineux? Emboles lymphatiques ++? Lésion adénocarcinoïde? Résection R1)
- *Pas d'indication à une surveillance si taille < 1 cm*
- *L'indication de colectomie complémentaire doit de plus en plus se discuter et se faire de moins en moins.*